To bolster its research and development abilities in the country, global pharma major Bristol-Myers Squibb will be investing about $300 million over eight years through its agreements with Biocon and Accenture.
To bolster its research and development abilities in the country, global pharma major Bristol-Myers Squibb will be investing about $300 million over eight years through its agreements with Biocon and Accenture.
Under the agreement entered by Bristol-Myers with Biocon, it will work with its subsidiary Syngene International to establish a research facility in Bangalore housing more than 400 scientists, a company statement said.
You have exhausted your monthly limit of free stories.
Read more stories for free with an Express account.
In a separate multi-year agreement, Bristol-Myers would expand its relationship with Accenture to include support for clinical data, document management, pharmacovigilance and scientific writing functions in India.
Accenture would also provide maintenance and support for R&D information systems and Bristol-Myers would utilise its life science centres in Bangalore and Chennai.
